|
1. Biologie
|
|
|
|
|
|
|
|
|
At
this stage, it is too early to tell people to avoid fatty foods,
cautions Lengyel — especially people with cancer who may need a
high-energy diet. “That’s a very dangerous message,” he says.
|
|
|
|
|
|
|
3.1.1 Tabac - e-cigs
|
|
|
|
|
|
|
|
|
In
his report Thursday, Murthy said it was “crucial” that progress made in
reducing conventional cigarette smoking among youth and young adults
“not be compromised by the initiation and use of e-cigarettes.”
|
|
|
|
|
|
|
|
|
|
|
|
|
The
report concluded with a “call to action” that includes urging the Food
and Drug Administration to put previously approved regulations into
effect. The agency in May passed final rules governing e-cigarettes, but
many of them will take several years to take full effect.
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
|
|
|
|
September
was Prostate and Thyroid Cancer Awareness Month, October was Breast
Cancer Awareness Month, and November was Lung Cancer Awareness Month. We
should designate December as Cancer Overdiagnosis Awareness month,
because a lot of cancers diagnosed by screening tests will never kill
you.
|
|
|
|
|
|
|
4.13 Dép., diag. & prono. - Peau
|
|
|
|
|
|
|
|
|
People
said their preferred method of finding out their skin biopsy results
largely relies on the amount of information the clinician needs to relay
and the amount of time it takes to receive the results, researchers
report in JAMA Dermatology.
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
|
|
|
|
|
Researcher Pandolfi outlines promising paths for cures, including targeted therapy, RNA medicine, and immune therapy.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
|
|
|
|
In
attempting to develop more effective approaches to targeting RAS,
Rosenberg’s team isolated tumor infiltrating lymphocytes (TILs) that
targeted the KRAS G12D mutation from tumor nodules in the patient’s
lungs that developed after colorectal cancer cells had spread to the
lungs. TILs are white blood cells that migrate from the bloodstream into
a tumor. The isolated TILs were grown in the laboratory to large
numbers and then infused into the patient intravenously.
|
|
|
|
|
|
|
|
|
|
|
|
|
Dr.
June said the research was the first successful targeting of a defect
in a gene called KRAS, and is important because mutations in the gene
are so common.
Still, he said, the big question is whether this case is “one in a million, or something that can be replicated and built upon?”
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
|
|
|
|
Usman
‘Oz’ Azam has taken the helm of Tmunity Therapeutics in Philadelphia,
which was founded by one of Penn’s star scientists, Carl June, with an
eye to developing new, curative cell therapies. It launched in January
with $10 million in backing from Penn Medicine, the academic medical
center of the University of Pennsylvania, and Lilly Asia Ventures.
|
|
|
|
|
|
|
5.12.4 Immunothérapies - Essais
|
|
|
|
|
|
|
|
|
Out
of 17 patients with an average age of 63 who received the vaccine, 12
are still in remission four years or more after receiving the vaccine,
Avigan and his co-authors at the Dana-Farber Cancer Institute report.
|
|
|
|
|
|
|
5.13 WCLC
|
|
|
|
|
|
|
|
|
The
median PFS was 3.3 month in cohort 2 of patients with high PD-L1, 1.9
month in same cohort but in patients with low/negative PD-L1. It was 2.4
month in cohort 3.
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
|
|
|
Rather
than a symptom of general played-outness, seeing big drug companies
doing deals with smaller outfits is a sign that everything is working as
it should. We should panic if that stops.
|
|
|
|
|
|
|
|
|
|
|
|
|
The
drug tucatinib — formerly known as ONT-380 in the pre-makeover days —
is a HER2 inhibitor that has been matched up with Herceptin and Xeloda
in combatting treatment-resistant breast cancer. It’s a pill, intended
to get through the blood-brain barrier to help some desperately ill
patients.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
|
|
|
|
|
O’Neill
has proposed that the FDA only require companies to prove drugs are
safe before they are sold – not that they actually work. O’Neill has
also said that organ donors should be allowed to be paid.
|
|
|
|
|
|
|
|
|
|
|
|
|
As
a result, instead of assuring patients an independent voice at the FDA,
the meetings with so-called patient and consumer advocacy groups might
have given the pharmaceutical lobby additional avenues for promoting its
agenda.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
|
|
|
|
"If
the drug companies think that they're going to continue to have free
rein to set and raise drug prices because of Trump, I think they're
deluding themselves," said Erik Gordon, professor at the University of
Michigan Ross School of Business. "Nobody who voted for him is in favor
of high drug prices."
|
|
|
|
|
|
|
5.7.1 SABCS-communiqués
|
|
|
|
|
|
|
|
|
Analysis Also Demonstrated Intracranial Median Progression-Free Survival (PFS) of 18.4 Months.
|
|
|
|
|
|
|
5.7.2 SABCS-divers
|
|
|
|
|
|
|
|
|
In
the study, 97 were randomized to veliparib plus carboplatin and
paclitaxel, 99 to placebo plus carboplatin and paclitaxel, and 94 to
veliparib plus chemo med temozolomide. Today’s read-out is from the
findings from the carboplatin and paclitaxel with veliparib or placebo
arms.
|
|
|
|
|
|
|
|
|
|
|
|
|
The
PARP race has been attracting considerable attention this year,
especially after Pfizer stepped in to buy Medivation and its late-stage
PARP in a $14 billion deal. Just weeks ago AstraZeneca whet investors
appetites when it said its Phase III study has produced solid supporting
data. Tesaro and Clovis, meanwhile, are also racing for an approval.
|
|
|
|
|
|
|
5.7.3 SABCS-AACR
|
|
|
|
|
|
|
|
|
The
overall response rate for the veliparib arm was 77.8 percent compared
with 61.3 percent for the placebo arm. The improvement in
progression-free survival in the veliparib arm (14.1 months versus 12.3
months) was not statistically significant. The trend to improved overall
survival was also not statistically significant (28.3 months versus
25.9 months).
|
|
|
|
|
|
|
|
|
|
|
|
|
Extended
letrozole therapy did not improve OS. However, a statistically
significant improvement in BCFI was noted, with a 29 percent reduction
in the risk of breast cancer recurrence or cancer in the opposite breast
as a first event. Additionally, a 28 percent statistically significant
reduction in the cumulative risk of DR was observed.
|
|
|
|
|
|
|
|
|
|
|
|
|
Analysis
conducted after 98 patients had disease progression showed that median
progression-free survival was 10.4 months among patients assigned
everolimus, compared with 5.1 months among those assigned placebo.
|
|
|
|
|
|
|
|
|
|
|
|
|
In
contrast to the published studies of primary, treatment-naïve breast
tumors, this research focuses on metastatic tumor samples from patients
with resistant disease, explained lead author of the study Ofir Cohen,
PhD, a postdoctoral researcher and computational biologist at the Broad
Institute and DFCI.
|
|
|
|
|
|
|
|
|
|
|
|
|
“We
found that for patients with no proof of cancer in the axillary lymph
nodes before neoadjuvant chemotherapy, SLNB during the surgery after
neoadjuvant chemotherapy was safe because those who had a negative SNLB
and did not have an ALND had a very low risk of an axillary relapse at
three years after surgery,” continued Classe, who is also professor of
oncology at the Medical University in Nantes.
|
|
|
|
|
|
|
5.8.4 ASH - CAR T
|
|
|
|
|
|
|
|
|
KTE-C19 will likely play an important role in the future treatment of DLBCL and other aggressive NHL subtypes.
|
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
|
|
|
|
We
advise people working in health and social care to make sure mothers
and fathers, brothers and sisters, get the practical and emotional
support they need to care for a family member at the end of life.
|
|
|
|
|
|
|
|
|
|
|
|
|
Where
is the research on what cancer patients see as significant risk? None
of the existing quality-of-life tools are adequate – apart from anything
else they measure a researcher’s view of the criteria that matter, not a
patient view.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
|
|
|
|
|
"The only good news we see in 2015 was that the cancer death rate continued to decrease," said Jiaquan Xu.
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
|
|
|
|
|
|
NHS
England’s chief executive, Simon Stevens, has announced the first
hospitals to benefit from the major national investment in radiotherapy
machines, alongside £200m of funding over two years.
|
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
|
|
|
|
|
Critics
note that the money described in the bill must be appropriated by
separate funding bills and that the money may ultimately never
materialize. Yet the changes to the clinical trial process, something
long sought by the drug industry, will be set in stone regardless of
whether money for the research projects is forthcoming.
|
|
|
|
|
|
|
|
|
|
|
|
|
Thankfully,
due to breakthroughs in precision medicine and renewed federal
commitment to cancer research, most patients with cancer have better
treatment outcomes than ever before. Today’s passage of the 21st Century
Cures Act will help us continue this momentum and build on this
incredible scientific progress to offer all patients hope and better
treatment options.
|
|
|
|
|
|
|
|
|
|
|
|
|
Expect
more Vioxx disasters, now that the 21st Century Cures Act threatens to
turn the FDA into a puppet of the pharmaceutical and medical device
industry. Also expect pharmaceutical company profits to soar. I hope
ASCO and the other medical groups that pushed for this bill think it was
worth it.
|
|
|
|
|
|
|
|
|
|
|
|
|
The
bill gives the health institutes the authority to finance high-risk,
high-reward research using special procurement procedures, as opposed to
more conventional grants and contracts. It also requires the agency’s
director to establish “Eureka prize” competitions to advance biomedical
research and improve treatments for serious illnesses.
|
|
|
|
|
|
|
|
|
|
|
|
|
The bill is now on its way to Barack Obama’s desk. On Wednesday, he said he looked forward to signing it.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
|
|
|
|
|
Initiatives
such as CancerLinQ address the urgent need to break down barriers that
impede progress in our fight against cancer. By analyzing patient
medical records and using in-memory computing technology to uncover
trends among millions of cancer patients—and sharing that knowledge—we
can enable more data-driven decision-making.
|
|
|
|
|
|